Hyderabad-based pharma company Laurus Labs Limited announced on Tuesday that it has entered into a strategic partnership agreement with Global Fund for a period of 3.5 years. Through this agreement Laurus Labs will have the volume commitments from the Global Fund for the treatment of HIV/AIDS.
The company has already received and executed the order from the global charity agency which would cater to the supples of the high burden diseases countries in Sub Saharan African(SSA) region. This is also the maiden order for Tenofovir/Lamivudine/Dolutegravir 300/300.50 mg(TLD) after the company has received a tentative approval from the US Food and Drug